These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34755091)

  • 1. The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas.
    Yan X; Zhou Q; Zhu H; Liu W; Xu H; Yin W; Zhao M; Jiang X; Ren C
    iScience; 2021 Nov; 24(11):103249. PubMed ID: 34755091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma.
    Zhou Q; Wei M; Shen W; Huang S; Fan J; Huang H
    Front Genet; 2022; 13():899883. PubMed ID: 35910221
    [No Abstract]   [Full Text] [Related]  

  • 3. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
    Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
    Front Oncol; 2020; 10():586019. PubMed ID: 33425739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
    Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
    Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in intratumoral and peripheral immune status in recurrent gliomas and their prognostic implications for patients underwent reoperation.
    Ou A; Hu W; Jiang P; Lu J; Zheng Y; Ke C; Mou Y; Sai K; Li D
    Int Immunopharmacol; 2024 Oct; 140():112797. PubMed ID: 39083926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

  • 9. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
    Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional Characteristics of
    Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
    Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
    [No Abstract]   [Full Text] [Related]  

  • 12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
    Liu S; Wang Z; Wang Y; Fan X; Zhang C; Ma W; Qiu X; Jiang T
    Oncoimmunology; 2018; 7(2):e1382792. PubMed ID: 29308304
    [No Abstract]   [Full Text] [Related]  

  • 16. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas.
    Deng X; Chen K; Ren J; Zeng J; Zhang Q; Li T; Tang Q; Zhu J
    Front Mol Biosci; 2022; 9():849723. PubMed ID: 35928223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas.
    Xie Q; Huang X; Huang W; Liu F
    Front Oncol; 2022; 12():860640. PubMed ID: 35756621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.